NIPH Clinical Trials Search

Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis

Basic Information

Recruitment status	Complete: follow-up complete
Health condition(s) or Problem(s) studied	diabetic patients undergoing hemodialysis
Date of first enrollment	2013/05/27
Target sample size	10
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	teneligliptin

Outcome(s)

Primary Outcome	The improvement of glycemic control evaluated by area under the curve (AUC) using continuous glucose monitoring in the treatment with teneligliptin for 4 weeks
Secondary Outcome	The changes of glyated albumin (GA) and bone metabolic markers in the treatment with teneligliptin for 4 weeks

Key inclusion & exclusion criteria

Age minimum	20years-old
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	Patients with severe liver dysfunction (AST more than 100 or ALT more than 100 IU/L) Patients with malignancy under medical treatmennt Patients with untreated diabetic retinopathy Patients terated with insulin injection Patients disqualified by doctor for any reason